Диссертация (1335885), страница 34
Текст из файла (страница 34)
The effect of generic competition on the price of brend-name drugs// Healf policy.-2004.-Apr.-68(10.-p.47-54.185.Lucki I. The forced swimming test as a model for core andcomponent behavioral effects of antidepressant drugs.//Behav. Pharmacol. –1997. – 8/ - p. 523 – 532.186.Lucouras E., Christodoulou G.N., Malliaras D., Stefanis C. Theprognostic importance of delusions in depression: A 6-year prospective followup study//J.Affect Disord.-1994.-32.-233-238.187.Maes M., Song C.
, Lin A.H., Bonaccorso S. et al.Negativeimmunoregulatory effects of antidepressants: Inhibition of interferon-gamma andstimulation of interleukin-10 secretion.//Neuropsychopharmacology.-1999.-20.p.370-379.188.Maier W., Benkert O.Treatment of chronic depression withsulpiride: evidence of efficacy in placebo-controlled single case studies.//Psychopharmacology.-1994.- 115.-p. 495–501.189.Mailman R.B., Murthy V. Third generation antipsychotic drugs:partial agonism or receptor functional selectivity?//Curr.Pharm Des.-2010.16(5).-488-501.190.Maina G., Vitalucci A., Gandolfo S., Bogetto F. Comparativeefficacy of SSRIS and amisulpride in burning mouth syndrome: a single – blindstudy.
// J. Clin. Psychiat. – 2002. – 63. – 1. – p. 38 – 43.191.MajM.,PirozziR.,Malianostudy.//J.Clin.Psychiatry.-2007.-68(9).-p.1411-1417.L.etal.follow-up181192.Malhi G.S., Adams D., Cahill C.M., Dodd S., Berk M. Themanagement of individuals with bipolar disorder: a review of the evidence andintegration into clinical practice.// Drugs. – 2009. – 22.
– 69(15). – p. 2063-2101.193.Marangell L.B., Johnson C.R., Kertz B., Zboyan H.A., MarttinezJ.M. Olanzapine in the treatment of apathy in previously depressed participantsmaintained with selective serotonin reuptake inhibitors: an open – label. flex: bledose study.// J.Clin.Psychiatry. – 2002. – 63(5).
– p. 391 – 395.194.Marketing Authorization of Pharmaceutical Products with SpecialReference to Multisource (Generic) Products. A manual for a Drug RegulatoryAuthority. World Health Organization, Geneva, 1999.195.Matthews J.D., Siefert C., Dording C., Denninger J.W., Park L., van.Nieuwenhuizer A.O., Sklarsky K., Hilliker S., Homberger C., Rooney K., FavaM. An open study of aripiprazole and escitalopram for psychotic majordepressive disorder.// J. Clin. Psychopharmacol. – 2009. – 29(1). – p.
73-76.196.Mc Inture R.S., Konarski J.Z. et al. Measuring the severity ofdepression and remission in primary care:nvalidation of the HAMD-7scale.//CMAJ. – 2005. – 11. – 22. – p. 173-178.197.Mc Inture R.S., Muzina D.J., Adams A., Lourenco M.T., Law C.W.,Soczynska J.K., Woldeyohannes H.O., Nathanson J., Kennedy S.H. Quentiapinexr efficacy and tolerability as monotherapy and adjunctive treatment toconventional antidepressant of major depressive disorder: a review of registrationtrials.// Expert Opin Pharmacother. - 2009. – 10(18).-p.3061 – 3075.198.Meyers B.S., Flint A.J., Rothchild A.J., Mulsant B.H., Whyte E.M.,Peasley – Miklus C., Papademetrrion E., Leon A.C., Heo M.; STOP-PD – Group.A double – blind randomized controlled trial of olanzapine plus sertraline vsolanzapine plus placebo for psychotic depression: the study of pharmacotherapyof psychotic depression.// Arch.
Gen. Psssychiatry. – 2009. – 66(8). – p. 838-847.199.Miller A.H., Malevic V., Raison C.L. Inflammation and itsdiscontents: the role of cytokines in the pathophysiology of majordepression.//Biol. Psychiatry.- 2009.-65.-9.-p.732-741.182200.Monhamed S., Leslie D.L., Rosenheck R.A. Use of antipsychotics inthe treatment of major depressive disorder in the U.S. Department of VeteransAffairs.// J. Clin. Psychiatry.
– 2009. – 70(6). – p. 906-912.201.Monroe S.M., Harknes K.L. Recurrence in major depression: aconceptual analysis//Psychol.rev.-2011.-118.-4.-p.655-674.202.Montgomery S.A. Dopaminergic deficit and the role of amisulpridein the treatment of mood disorders.//J. Clin. Psychopharmacol. – 2002. – 17. – 4.– p.9-15.203.Montgomery S. Milnacipran: a review.//Jnt. Clin. Psychopharmacol.– 2003.
– 18. – suppl. 1. – p. 1 – 9.204.MöllerH.J.Эффективностьамисульпиридаприлечениишизофрении. Обзор литературы (расширенный реферат). // Психиатрия ипсихофармакотерапия. – 2004. – 6. -3. – с. 136 – 141.205.Muller-SiechenederF., Muller M.J., Hillert A., et al (1998)Risperidone versus haloperidol and amitriptyline in the treatment of patients withcombinedpsychoticanddepressivesyndrome.//JournalofClinicalPsychopharmacology.-18.-p. 111-120.206.Multisource (generic) pharmaceutical products: guidelines onregistration requirements to establish interchangeability.//WHO Technical ReportSeries.
- N863.- 1996.- p.114-154.207.Neghtingale C.H. A survey of the Quality of Generic ClarithromydnProduct from 13 Contries// Clin.Drug Jnvest.-2000.-19.-p.293-295.208.Nelson J.C., Mankoski R., Baker R.A., Carlson B.X., Eudicone J.M.,Rikalov A., Tran Q.V., Berman R.M. Effects of aripiprazole adjunctive tostandard antidepressant treatment on the core symptoms of depression: a posthoc, pooled analysis of two large, placebo – controlled studies.// J. Affect Disord.– 2010. – 120(1-3). – p. 133-140.209.Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation inmajor depressive disorder: a meta-analysis of placebo-controlled randomizedtrials.// Am J.
Psychiatry. – 2009. – 166(9). – p. 980-991.183210.Nelson J.C., Pikalov A., Berman R.M. Augmentation treatment inmajor depressive disorder focus on aripiprazole.//Neuropsychiatr Dis. Treat.2008.-4(5).-p.937-948.211.Nemeroff C.B., Gharabawi G.M., Canuso C.M. Augmentation withrisperidone in chronic resistant depression: a double – blind placebo – controlledmaintenance trial.// Neuropsychopharmacology – 2004.– 29.- p. 5159.212.Niereberg A.A. et al.
Early nonresponse to fluoxetine as a predictorof poor 8 – week outcome. //Ain. J. Psychiatry. – 1995. – 152. – p. 1500 – 1503.213.Niskanen P., Tamminen T., Viukaru M. Sulpiride vs. amitriptylinein the treatment of depression.// Current Ther. Res. -1975.- 17.-p. 281–284.214.Oliver J.S., Ignatiadis S., Maruff P., Burrows G.D., Norman T.R.Quentiapine augmentation in depressed patients with partial response toantidepressants. // Hum. Psychopharmacol. – 2008.
– 23(8). – 653 – 660.215.Ostroff R.B., Nelson J.C. Risperidone augmentation of selectiveserotonin reaptake inhibitors in major depression. // J. Clin. Psychiatry. – 1999. –Apr. 60 (4). – 256 – 259.216.Owenby R.R., Brown L.T., Brown J.N. Use of risperidone asaugmentation treatment for major depressive disorder.//Ann. Pharmacoter.-2011.45(1).-p.95-100.217.Parker G. Antidepressants on trial: how valid is the evidence.// Brit.J.
Psychiatry. – 2009. – 194(3). – p. 1-3.218.Papacostas G.I. Augmentation of standard antidepressants withatypical antipsychotic agents for treatment-resistant major depressive disorder.//Essential Psychopharmacology. – 2005. – 6. – p. 209 – 220.219.Papacostas G.I. Managing partial response: swiching, augmentation,and combination strategies for major depressive disorders.// J.Clin.
Psychiatry.2009. - 6. - p. 16-25.220.Papacostas G.I., PetersenT.J., Kinrys G. et al. Aripiprazoleaugmentation of selective serotonin reuptake inhibitors for treatment-resistant184major depressivedisorder.//Journal of Clinical Psychiatry.-2005.-66.-p.1326-1300.221.Papacostas G.I., Petersen T.J., Nierenberg A.A. et al. Ziprasidoneaugmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRIresistant major depressive disorder.//Journal of clinical Psychiatry.-2004.-65.p.217-221.222.Perlis R.H., Adams D.H., Fijal B., Sutton V.K., Farmen M., BreierA., Houston J.P. Genetic association study of treatment response witholanzapine/fluoxetine combination or Lamotrigine in bipolar depression.// J.Clin.Psychiatry.-2009.-15.-[E pub ahead of print].223.Peuskens J., Möller H.J., Puech A.
et al. Amisulpride improvesaffective symptoms in acute schizophrenia.// World J Biol Psychiatry.-2001.- 2.1.- p. 21-28.224.Peuskens J., Moller H.J., Puech A. Amisulpride improves depressivesymptoms in acute exacerbations of schizophrenia: comparison with haloperidoland risperidone. // Eur. Neeuropsychopharmacol. – 2002. – 12.-4. – p. 305 – 310.225.Pintor L., Gasto C., Navarro V. et al. Relapse of major depressionafte complete and partial remission during a 2-year follow-up.//J.
Affect. Disord.2003. – 73.-p.237-244.226.Pitchot W., Ansseau M. Addition of olanzapine for treatment –resistant depression.//Am. J. Psychiatry. – 2001. – Oct. 158 (10). – p. 1737 –1738.227.Porsolt R. D., Lenegre A., McArthur R. A. Pharmacological, modelsof depression. In Olivier B, Mos J, Slangen J L (eds).//Animal models inpsychopharmacology.- Birkhäuser Verlag.- Basel.-1991.- p. 137–160228.Potkin S.G., Thyrum P.T., Alva G., Carreon D., Yeh C., Kalali A.Arvanitis L.A. Effect of fluoxetine and imipramine on the pharmacokinetics andtolerability of the antipsychotic quentiapine.//J. Clin.
Psychopharmacol. – 2002. –Apr. 22 (2). – p. 174 – 182.185229.Poyurovsky M., Pashinian A., Gil – Ad I., Maayan R., SchneidmanM., Fuchs C.,Weizman A. Olanzapine – induced weight gain inn patients withfirst – episode schizophrenia : a double – blind, placebo – controlled study offluoxetine addition. //Am. J.
Psychiatry. – 2002. – Jun. 159 (6). – p. 1058 – 1060.230.Porsolf R.D., Lenegre A., Mc Arthur R.A. Pharmacological, modelsdepression. Jn: Animal models in psychopharmacology. B. Olivier, J. Mos, J.L.Hangen (eds).//Birkhäuser Verlag, Basel. – 1991. – p. 137 – 160.231.Preskorn S.H. Treatment options for the patient who does notrespond well to initial antttttttidepressant therapy.//J.Psychiatr.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
